PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study.
GRPR affinity
NIR fluorescent dyes
PESIN multimers
cell binding
copper-64
gallium-68
indocyanine dyes
multimodal imaging
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
02 Jun 2021
02 Jun 2021
Historique:
received:
26
04
2021
revised:
27
05
2021
accepted:
28
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Recently, anionic charges were found to negatively influence the in vitro gastrin-releasing peptide receptor (GRPR) binding parameters of dually radioisotope and fluorescent dye labeled GRPR-specific peptide dimers. From this, the question arose if this adverse impact on in vitro GRP receptor affinities could be mitigated by a higher valency of peptide multimerization. For this purpose, we designed two different hybrid multimodal imaging units (MIUs), comprising either one or two click chemistry-compatible functional groups and reacted them with PESIN (PEG
Identifiants
pubmed: 34199635
pii: ph14060531
doi: 10.3390/ph14060531
pmc: PMC8226452
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : WA3555/5-1
Références
Chem Rev. 2010 May 12;110(5):3087-111
pubmed: 20225899
Angew Chem Int Ed Engl. 2019 Feb 25;58(9):2570-2579
pubmed: 29968300
Bioconjug Chem. 2020 Feb 19;31(2):248-259
pubmed: 31909595
Biochem Pharmacol. 2005 Feb 15;69(4):579-93
pubmed: 15670577
Dalton Trans. 2019 Oct 7;48(39):14547-14565
pubmed: 31556418
J Nucl Med. 2020 Aug;61(8):1113-1122
pubmed: 32303598
Chem Rev. 2010 May 12;110(5):2575-8
pubmed: 20415501
Nat Biotechnol. 2001 Apr;19(4):327-31
pubmed: 11283589
Angew Chem Int Ed Engl. 2021 Mar 15;60(12):6230-6241
pubmed: 32959963
J Mater Chem B. 2018 May 7;6(17):2541-2546
pubmed: 32254472
Br J Pharmacol. 2013 Jun;169(4):719-35
pubmed: 23488622
Bioconjug Chem. 2014 Mar 19;25(3):489-500
pubmed: 24533789
J Nucl Med. 2008 Feb;49(2):169-72
pubmed: 18199608
Bioconjug Chem. 2003 Sep-Oct;14(5):1048-51
pubmed: 13129411
Chemistry. 2017 Jul 12;23(39):9306-9312
pubmed: 28339120
Chemistry. 2019 Jan 2;25(1):43-59
pubmed: 30095185
ChemMedChem. 2015 Jul;10(7):1200-8
pubmed: 26011290
J Nucl Med. 2011 Apr;52(4):586-91
pubmed: 21421712
Chem Rev. 2010 May 12;110(5):3146-95
pubmed: 20225900
J Med Chem. 2013 Jan 24;56(2):406-16
pubmed: 23214723
Biochem Biophys Rep. 2015 Oct 31;4:375-385
pubmed: 29124227
Chem Rev. 2019 Jan 23;119(2):870-901
pubmed: 30299088
J Med Chem. 2005 Oct 6;48(20):6286-95
pubmed: 16190755
Nat Rev Cancer. 2013 Sep;13(9):653-62
pubmed: 23924645
J Nucl Med. 2019 Mar;60(3):299-303
pubmed: 30733314
J Am Chem Soc. 2020 Feb 19;142(7):3430-3439
pubmed: 32040300
Nat Med. 2011 Sep 18;17(10):1315-9
pubmed: 21926976
Chem Commun (Camb). 2018 Nov 22;54(94):13196-13199
pubmed: 30334022
Pharmaceuticals (Basel). 2020 Sep 16;13(9):
pubmed: 32948032
J Mater Chem B. 2020 Dec 14;8(46):10602-10608
pubmed: 33136101
Oncotarget. 2017 Feb 28;8(9):15407-15419
pubmed: 28039488
J Org Chem. 2006 Sep 29;71(20):7862-5
pubmed: 16995699
Med Res Rev. 2013 Jan;33(1):3-32
pubmed: 23239045
J Med Chem. 2020 Mar 12;63(5):2426-2433
pubmed: 31855417
J Med Chem. 2002 May 9;45(10):2003-15
pubmed: 11985468
Mol Pharm. 2019 Mar 4;16(3):1412-1420
pubmed: 30714739
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
J Mater Chem B. 2020 Feb 14;8(6):1302-1309
pubmed: 31967633
Biochemistry. 2010 Feb 23;49(7):1364-76
pubmed: 20102226
Technol Cancer Res Treat. 2004 Aug;3(4):393-409
pubmed: 15270591
Proteins. 2002 Oct 1;49(1):1-6
pubmed: 12211010
Phys Med Biol. 2012 May 21;57(10):3123-36
pubmed: 22547491
Bioconjug Chem. 2018 Nov 21;29(11):3886-3895
pubmed: 30354072
Chemistry. 2020 Dec 9;26(69):16349-16356
pubmed: 32618007